Skip to main content

Vaginal Moisturizers & Lubricants

Vaginal moisturizers and lubricants are nonhormonal options for genitourinary syndrome of menopause (GSM) and vulvovaginal dryness. They sit alongside vaginal estrogen, vaginal DHEA, and ospemifene among the GSM treatment options, and are the default starting point for women who prefer to avoid hormones or for whom hormones are relatively contraindicated — most importantly survivors of estrogen-dependent breast cancer.[3] For the reconstructive surgeon and urogynecologist, they matter as a low-risk adjunct for tissue comfort before and after pelvic surgery, for pessary tolerance, and for symptom relief alone or alongside other GSM treatment.

Moisturizers Versus Lubricants​

The two product classes are frequently conflated but serve distinct roles.[1][2]

Vaginal moisturizerVaginal lubricant
PurposeTrap moisture, restore mucosal hydration, longer-term symptom controlReduce friction and dyspareunia at intercourse
SiteApplied intravaginallyApplied at the introitus / vaginal opening
ScheduleRegular use, 2–3 times per weekAs-needed, immediately before intercourse
Effect on tissueSustained improvement in dryness, pH, elasticity, itching, irritationTransient lubrication only

Prospective studies of regular moisturizer use show measurable improvement in vaginal dryness, pH balance, and elasticity, with reductions in itching, irritation, and dyspareunia.[1][2]

Vaginal Moisturizers​

Formulations​

  • Hyaluronic acid–based and polycarbophil-based products are the most commonly used moisturizers.[2]
  • Polyacrylic acid and vitamin E / vitamin D vaginal suppositories are additional nonhormonal options with reported efficacy.[2][3]
  • Regulatory classification is product-specific: many US personal lubricants/moisturizers are medical devices, including products cleared through FDA 510(k), rather than cosmetics or prescription hormone drugs.[15] Some contain potential mucosal irritants such as parabens and propylene glycol — relevant in patients with vulvar dermatoses or sensitive tissue.[2]

Evidence​

The evidence base is meaningful but of low certainty.

  • A 2024 systematic review (Annals of Internal Medicine, 46 RCTs) found that vaginal moisturizers may improve dryness versus placebo, with low certainty of evidence. The same review rated vaginal estrogen, vaginal DHEA, and oral ospemifene as also improving GSM symptoms with similarly low certainty.[4]
  • The Mitchell 2018 RCT (JAMA Internal Medicine, n = 302) compared vaginal estradiol, a polycarbophil-based moisturizer, and dual placebo in women with moderate-to-severe vulvovaginal symptoms. All three groups improved similarly, with no significant difference between either active treatment and placebo.[5] This is interpreted either as a strong placebo effect from regular vaginal gel application, or as evidence that the moisturizing properties of the placebo gel were themselves therapeutic.
  • A 2023 systematic review of nonestrogen GSM therapies (Obstetrics & Gynecology) reinforced that moisturizers are an evidence-supported nonhormonal option without a clear best-in-class formulation.[8]

Moisturizers Versus Vaginal Estrogen​

The Garcia de Arriba 2022 RCT (n = 172) found a hormone-free moisturizing cream non-inferior to 0.1% estriol cream for mild-to-moderate vulvovaginal dryness over 43 days. In the severe-symptom subgroup, estriol cream was significantly superior (p = 0.0032).[6] This short, product-specific study does not establish a universal treatment hierarchy. AUA/SUFU/AUGS 2025 recommends moisturizers/lubricants alone or with other therapies; general GSM care does not require failure of moisturizers before low-dose vaginal estrogen.[14]

Vaginal Lubricants​

Lubricants are applied to the introitus before intercourse to reduce friction and dyspareunia, on an as-needed basis. ACOG endorses them as a nonhormonal option for friction-related dyspareunia.[1]

Lubricant Types​

TypeAdvantagesDisadvantagesCondom-compatible
Water-basedWidely available, easy cleanupDries out quickly causing friction; many are hyperosmolarCheck product and condom labeling
Silicone-basedLong-lasting, does not dry out, formulation-specific tolerabilityIncompatible with silicone toys; more expensiveCheck product and condom labeling
Oil-based (food-grade)Inexpensive, long-lastingDegrades latex condoms; may raise infection riskNo (latex)
Hyaluronic acid–basedPossible mucosal benefitLimited comparative dataVaries by product

No lubricant type has proven superior overall; selection should account for condom compatibility, patient sensitivities, and preference.[2]

Osmolality and pH — An Underappreciated Selection Criterion​

The osmolality and pH of a lubricant materially affect vaginal mucosal health. The WHO/UNFPA/FHI360 advisory distinguished an ideal osmolality ≤380 mOsm/kg from an interim procurement ceiling ≤1200 mOsm/kg; the latter is not an iso-osmolar definition. Select pH and condom/fertility compatibility for the intended use rather than applying one range to every product.[16][9][10] Many commercial lubricants are markedly hyperosmolar.

  • Dezzutti 2012 evaluated 14 over-the-counter lubricants: hyperosmolar products (including KY Jelly and Astroglide) caused epithelial cell toxicity, tissue damage, and Lactobacillus toxicity, whereas iso-osmolar products (e.g., Good Clean Love, PRÉ) and silicone-based lubricants showed no significant epithelial damage.[11]
  • Wilkinson 2019 confirmed in 3-dimensional vaginal epithelial-cell models that hyperosmolar lubricants alter cell morphology and are selectively cytotoxic, inflammatory, and barrier-disrupting.[12]
  • Palacios 2023 RCT (n = 174) showed that lubricants formulated to meet WHO osmolality guidelines were equally effective at improving sexual function (FSFI scores) and well tolerated — efficacy is not compromised by adherence to safer osmolality thresholds.[9]

Irritant and compatibility assessment​

Review formulation and concentration, patient irritation history, and condom/fertility compatibility. Avoid products that cause symptoms; high osmolality, spermicides, fragrances, and warming additives can be problematic. A named preservative alone does not establish clinical toxicity.[13][14]

Breast-Cancer Survivors​

ACOG's Clinical Consensus on urogenital symptoms in women with a history of estrogen-dependent breast cancer recommends nonhormonal methods — moisturizers and lubricants — as first-line treatment.[3]

  • In an RCT of breast-cancer survivors (n = 45), a polycarbophil-based lubricant was similar to a water-based lubricant for vaginal dryness but superior for reducing dyspareunia.[3]
  • A cohort study (n = 38) found a silicone-based lubricant gave greater symptomatic relief than a water-based lubricant in sexually active postmenopausal breast-cancer patients.[3]
  • Topical 4% aqueous lidocaine applied to the introitus for 3 minutes before intercourse is particularly effective for introital dyspareunia: in a double-blind trial of 46 breast-cancer survivors with severe penetrative dyspareunia, lidocaine reduced dyspareunia by 88% versus 38% for saline placebo.[3]

Guideline Recommendations​

The American College of Obstetricians and Gynecologists (ACOG) endorses over-the-counter nonhormonal moisturizers and lubricants as reasonable options for vaginal dryness and friction-related dyspareunia, particularly for women who prefer to avoid hormonal therapy.[1][2] The American Academy of Family Physicians similarly identifies over-the-counter hormone-free vaginal products as reasonable first-line therapy for GSM, with lubricants used as-needed for dyspareunia.[7] When lubricants or moisturizers are insufficient, escalation to vaginal estrogen, vaginal DHEA (prasterone), or oral ospemifene is guided by symptom severity and patient preference; breast-cancer survivors should discuss hormonal escalation with their oncologist.[3][7]

Reconstructive Relevance​

Moisturizers and lubricants may improve dryness and comfort around pelvic care, but they have not established improved surgical healing, prolapse-repair durability, or prevention of pessary erosion. Lubricant laboratory-toxicity studies do not prove postoperative infection prevention. Resume vaginal products and intercourse after reconstruction according to the operating team's healing assessment. See priming evidence.

Practical Use​

  • Moisturizers: intravaginal application 2–3 times per week for ongoing symptom control.[1][7]
  • Lubricants: applied at the introitus immediately before intercourse, as needed.[1][2]
  • Product selection: choose by comfort, cost, sensitivities, intended use, and product-specific condom compatibility. Lower-osmolality options may be preferable when available; 1200 mOsm/kg is an upper procurement limit, not a physiological target.[14][16]
  • Escalation: if nonhormonal products give insufficient relief, move to vaginal estrogen, vaginal DHEA (prasterone), or oral ospemifene.[7]

References​

1. Committee on Practice Bulletins—Gynecology. "ACOG Practice Bulletin No. 141: Management of Menopausal Symptoms." Obstet Gynecol. 2014;123(1):202–216. doi:10.1097/01.AOG.0000441353.20693.78

2. Committee on Practice Bulletins—Gynecology. "Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213." Obstet Gynecol. 2019;134(1):e1–e18. doi:10.1097/AOG.0000000000003324

3. Committee on Clinical Consensus–Gynecology. "Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer: Clinical Consensus." Obstet Gynecol. 2021;138(6):950–960. doi:10.1097/AOG.0000000000004601

4. Danan ER, Sowerby C, Ullman KE, et al. "Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause: A Systematic Review." Ann Intern Med. 2024;177(10):1400–1414. doi:10.7326/ANNALS-24-00610

5. Mitchell CM, Reed SD, Diem S, et al. "Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial." JAMA Intern Med. 2018;178(5):681–690. doi:10.1001/jamainternmed.2018.0116

6. Garcia de Arriba S, Grüntkemeier L, Häuser M, et al. "Vaginal Hormone-Free Moisturising Cream Is Not Inferior to an Estriol Cream for Treating Symptoms of Vulvovaginal Atrophy: Prospective, Randomised Study." PLoS One. 2022;17(5):e0266633. doi:10.1371/journal.pone.0266633

7. Chang JG, Lewis MN, Wertz MC. "Managing Menopausal Symptoms: Common Questions and Answers." Am Fam Physician. 2023;108(1):28–39.

8. Casiano Evans EA, Hobson DTG, Aschkenazi SO, et al. "Nonestrogen Therapies for Treatment of Genitourinary Syndrome of Menopause: A Systematic Review." Obstet Gynecol. 2023;142(3):555–570. doi:10.1097/AOG.0000000000005288

9. Palacios S, Hood S, Abakah-Phillips T, Savania N, Krychman M. "A Randomized Trial on the Effectiveness and Safety of 5 Water-Based Personal Lubricants." J Sex Med. 2023;20(4):498–506. doi:10.1093/jsxmed/qdad005

10. Potter N, Panay N. "Vaginal Lubricants and Moisturizers: A Review Into Use, Efficacy, and Safety." Climacteric. 2021;24(1):19–24. doi:10.1080/13697137.2020.1820478

11. Dezzutti CS, Brown ER, Moncla B, et al. "Is Wetter Better? An Evaluation of Over-the-Counter Personal Lubricants for Safety and Anti-HIV-1 Activity." PLoS One. 2012;7(11):e48328. doi:10.1371/journal.pone.0048328

12. Wilkinson EM, Łaniewski P, Herbst-Kralovetz MM, Brotman RM. "Personal and Clinical Vaginal Lubricants: Impact on Local Vaginal Microenvironment and Implications for Epithelial Cell Host Response and Barrier Function." J Infect Dis. 2019;220(12):2009–2018. doi:10.1093/infdis/jiz412

13. Vanderschee R, Kostov S. "Approach to Lubricant Use for Sexual Activity." Can Fam Physician. 2025;71(7-8):e158–e166. doi:10.46747/cfp.710708e158

14. AUA/SUFU/AUGS. Genitourinary Syndrome of Menopause Guideline. 2025. Official guideline.

15. FDA. CVS Personal Lubricant & Moisturizer, 510(k)K062682. Device clearance summary.

16. WHO/UNFPA/FHI360. Use and procurement of additional lubricants with male and female condoms. 2012. Advisory note.